Literature DB >> 7556050

Transection of the accessory ligament of the superficial digital flexor tendon for treatment of tendinitis: long term results in 61 standardbred racehorses (1985-1992).

P M Hogan1, L R Bramlage.   

Abstract

Medical records and lifetime race results were obtained for 61 Standardbred racehorses treated consecutively from 1985 to 1992 with transection of the accessory ligament of the superficial digital flexor tendon (AL-SDF) for tendinitis of one or both forelimbs. A clinical diagnosis of tendinitis was confirmed in all cases by ultrasonographic examination. After surgery, 50 (82%) horses raced and 42 (69%) completed 5 or more starts. Eight horses (13%) failed to start and/or complete 5 or more races due to a recurrence of tendinitis. Six (10%) horses did not start and/or complete 5 or more starts for reasons unrelated to tendinitis and 5 (8%) horses were lost to follow-up. The median time between surgery and the first post operative start was 39 weeks. Fifty-seven per cent of those horses to start after surgery completed 20 or more starts and 40% raced on 40 or more occasions. Of the 42 horses to complete 5 or more races, the median number of post operative starts was 37 at time of follow-up. Thirty-two of 50 (64%) horses to start after surgery established or lowered lifetime racemarks. Thirty-six horses had raced prior to surgery. Thirty-one of 36 (86%) horses returned to racing after treatment of SDF tendinitis with accessory desmotomy (AD) and 27 horses (75%) completed 5 or more starts. Median earnings per start decreased 25% after surgery. Twenty-five horses had not raced prior to surgery. Nineteen (76%) horses in this group were age 2 years at time of injury.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7556050     DOI: 10.1111/j.2042-3306.1995.tb03066.x

Source DB:  PubMed          Journal:  Equine Vet J        ISSN: 0425-1644            Impact factor:   2.888


  2 in total

1.  Evaluation of early cellular influences of bone morphogenetic proteins 12 and 2 on equine superficial digital flexor tenocytes and bone marrow-derived mesenchymal stem cells in vitro.

Authors:  Shannon J Murray; Kelly S Santangelo; Alicia L Bertone
Journal:  Am J Vet Res       Date:  2010-01       Impact factor: 1.156

2.  Randomized controlled trial demonstrates the benefit of RGTA® based matrix therapy to treat tendinopathies in racing horses.

Authors:  Sandrine Jacquet-Guibon; Anne-Gaelle Dupays; Virginie Coudry; Nathalie Crevier-Denoix; Sandrine Leroy; Fernando Siñeriz; Franck Chiappini; Denis Barritault; Jean-Marie Denoix
Journal:  PLoS One       Date:  2018-03-09       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.